The Association of FLT3-ITD Gene Mutation with Bone Marrow Blast Cell Count, CD34, Cyclin D1, Bcl-xL and hENT1 Expression in Acute Myeloid Leukemia Patients

Paulus Budiono Notopuro,Jusak Nugraha,Budi Utomo,Harianto Notopuro,Paulus Notopuro

DOI: https://doi.org/10.30699/ijp.2020.122579.2328

2020-10-01

Iranian Journal of Pathology

Abstract:BACKGROUND &amp; OBJECTIVE: &lt;AbstractText Label="BACKGROUND &amp; OBJECTIVE" NlmCategory="OBJECTIVE"&gt;<i>FLT3</i>-ITD has been recently used as a molecular prognostic marker for risk classification in acute myeloid leukemia (AML) therapy. In this study we aimed to investigate the association of <i>FLT3</i>-ITD gene mutation with bone marrow blast cell count, CD34 expression as malignant cell burden, cyclin D1 and Bcl-xL expressions as indexes of cell proliferation and anti-apoptosis and human equilibrative nucleoside transporter 1 (hENT1) expression as cytarabine transporter during AML treatment.&lt;/AbstractText&gt;METHODS: &lt;AbstractText Label="METHODS" NlmCategory="METHODS"&gt;We investigated <i>FLT3</i>-ITD mutations, bone marrow blast cell count, CD34, cyclin D1, Bcl-xL and hENT1 expression in bone marrow aspirates from 22 de novo AML patients in a cross sectional study.&lt;/AbstractText&gt;RESULTS: &lt;AbstractText Label="RESULTS" NlmCategory="RESULTS"&gt;<i>FLT3</i>-ITD mutations were observed in 5 out of 22 de novo AML patients (22.7%). Patient with <i>FLT3</i>-ITD mutations had higher blast cell counts (79.5% vs 56.1%, <i>P</i>=0.004). In patients with <i>FLT3</i>-ITD mutations, CD34 and cyclin D1 expressions were higher (MFI 328.80 vs 25.78, <i>P</i>=0.003 and MFI 74.51 vs 57.15 <i>P</i>=0.005) than the patients without mutations. hENT1 expression in AML with <i>FLT3</i>-ITD mutation was lower (MFI 29.64 versus 56.32, <i>P</i>=0.0000) than in mutation-free AML. There was no significant difference in Bcl-xL expression between patients with and without mutations (<i>P</i>=0.61).&lt;/AbstractText&gt;CONCLUSION: &lt;AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS"&gt;A significant association was found between <i>FLT3</i>-ITD gene mutations in AML patients with bone marrow blast cell count, CD34, cyclin D1 and hENT1 expressions, however no association was obtained with Bcl-xL expression. These findings support the role of such mutation in pathogenesis of AMLand its contribution in rearrangement of standard therapy with cytarabine in management of AML.&lt;/AbstractText&gt;